“Lynchpin molecule for the spread of cancer found”

This type of heading in media stories and press releases tends to drive your Sitemaster to distraction because there is almost invariably a major “may” or a “possibly” in the actual story when you get into the details. However, in this particular case there may be some justification for the headline. … READ MORE …

Olaparib continues to show promise in very late stage prostate cancer

According to a presentation at the ongoing annual meeting of the American Association for Cancer Research (AACR) meeting here in  Philadelphia, AstraZeneca’s PARP inhibiting agent — olaparib or Lynparza — continues to show promise in very late stage metastatic, castration-resistant prostate cancer. … READ MORE …

Does use of PDE5 inhibitors post-treatment affect risk for biochemical recurrence?

A new article in the February 2015 of the Journal of Urology may actually tell us as much (or more) about the difficulties of relying on data from large, retrospective analyses of single institution data as it does about the actual issue references in the headline above. … READ MORE …

Does olaparib have real potential in treatment of mCRPC?

According to a report on the Reuters web site yesterday, some researchers are of the opinion that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (recently recommended for approval in Europe for the treatment of a subset of women with ovarian cancer) may be valuable in the treatment of some forms of prostate cancer too. … READ MORE …

Bayer, Orion initiate Phase III trial of ODM-201 in non-metastatic CRPC

According to a media release today from Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company), they have started to  enroll patients in a randomized Phase III clinical trial of ODM-201, a novel, oral androgen receptor inhibitor in development for the treatment of men with advanced forms of prostate cancer. … READ MORE …

PARP inhibition, TMPRSS2-EPG gene fusion, and veliparib in mCRPC

A Phase II clinical trial being coordinated by researchers at the University of Michigan Cancer Center is (as far as we know) the first trial ever to explore the potential of treatment for men with metastatic, castration-resistant prostate cancer (mCRPC) who carry the TMPRSS2-EPG fusion gene (as opposed to those who do not). … READ MORE …

AT13387 in trials for treatment of men with mCRPC after progression on abiraterone

California-based Astex Pharmaceuticals has announced the initiation of a Phase I/II clinical trial of another heat shock protein 90 (HSP90) inhibitor (AT13387) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who have progressed after treatment with abiraterone acetate + prednisone (or a similar steroid). … READ MORE …